let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma
暂无分享,去创建一个
Jian Ma | Jian Ma | Jingtao Peng | Ren Mo | Jie Fan | Jie Fan | Ren Mo | Jingtao Peng
[1] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.
[2] Jie Fan,et al. Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma cell lines by targeting c-myc. , 2012, Biochemical and biophysical research communications.
[3] Xiaohong Song,et al. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway , 2008, Apoptosis.
[4] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[5] K. M. Nicholson,et al. The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.
[6] Y. Doki,et al. Let-7 Expression Is a Significant Determinant of Response to Chemotherapy through the Regulation of IL-6/STAT3 Pathway in Esophageal Squamous Cell Carcinoma , 2012, Clinical Cancer Research.
[7] L. O’Driscoll,et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma , 2009, BMC urology.
[8] Jingai Zhu,et al. microRNA expression profiling of the developing mouse heart. , 2012, International journal of molecular medicine.
[9] M. Oya,et al. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. , 2003, The Journal of urology.
[10] Jean-Jacques Patard,et al. EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.
[11] Lorenzo Marconi,et al. EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.
[12] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[13] Jie Fan,et al. Mechanism and function of decreased FOXO1 in renal cell carcinoma , 2012, Journal of surgical oncology.
[14] Sun-Mi Park,et al. Let‐7 modulates acquired resistance of ovarian cancer to Taxanes via IMP‐1‐mediated stabilization of multidrug resistance 1 , 2012, International journal of cancer.
[15] Sun-Mi Park,et al. The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.
[16] V. Leblanc,et al. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells. , 2013, Gynecologic oncology.
[17] Jia Yu,et al. Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells. , 2014, Die Pharmazie.
[18] C. Luo,et al. Knockdown of AKT2 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to the anticancer drug VM-26 in U87 glioma cells , 2012, Brain Research.
[19] J. Bellmunt,et al. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. , 2014, European journal of cancer.
[20] R. Recker,et al. let-7 MicroRNAs Induce Tamoxifen Sensitivity by Downregulation of Estrogen Receptor α Signaling in Breast Cancer , 2011, Molecular medicine.
[21] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[22] F. Erdoğan,et al. Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.
[23] C. Bokemeyer,et al. Chemotherapy for renal cell carcinoma. , 1999, Anticancer research.
[24] S. R. Datta,et al. Cellular survival: a play in three Akts. , 1999, Genes & development.
[25] Xiaohong Song,et al. Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. , 2009, Cancer letters.
[26] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[27] A. Toker,et al. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. , 2009, Cellular signalling.
[28] G. Z. Cheng,et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.
[29] D. Jacqmin,et al. The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy. , 2006, Cancer research.